Antibody drug conjugates (ADCs) represent one of the most advanced strategies in targeted therapy, particularly in oncology. These innovative treatments combine the precise targeting ability of monoclonal antibodies with the potent cell-killing power of chemotherapy drugs. By linking these two components through specialized chemical connectors, ADCs deliver toxic agents directly to cancer cells while sparing healthy tissue—a major advancement over traditional systemic therapies.
The foundation of an ADC lies in its three key components: the antibody, the cytotoxic drug, and the linker. The antibody serves as a guide, recognizing and binding to specific antigens present on cancer cells. Once attached, the conjugate is internalized, releasing the cytotoxic drug within the cell. This targeted approach allows for more effective tumor destruction while reducing side effects such as hair loss, immune suppression, and nausea.
Linker technology plays a crucial role in ADC performance. Stable linkers ensure the drug remains attached during circulation,…